Web Analytics

fundsforNGOs

Grants and Resources for Sustainability

You are here: Home / Latest Funds for NGOs and Calls for Proposals and Calls for Applications / Joint Call for Proposals: Precision Biotherapeutics-mRNA Therapeutics for Fostering High Performance Biomanufacturing under BioE3 Policy (India)

Joint Call for Proposals: Precision Biotherapeutics-mRNA Therapeutics for Fostering High Performance Biomanufacturing under BioE3 Policy (India)

Deadline: 15-May-25

DBT and BIRAC invites proposals on ‘Precision Biotherapeutics-mRNA therapeutics ‘under the Bio E3 policy to further the indigenous development and manufacturing of this important biotherapeutic.

Precision Biotherapeutics- mRNA Therapeutics has been identified as one of the thematic sectors under the BioE3 Policy for ‘fostering high-performance biomanufacturing’.

mRNA therapy can potentially transform existing therapies or target difficult indications, including respiratory, cardiac, metabolic and autoimmune diseases, as well as cancer. mRNA technology can be used for the following therapeutic applications:

  • Replacement therapy: to compensate for a defective gene/protein, or to supply therapeutic proteins.
  • Vaccines: mRNA encoding specific antigen(s) to elicit protective immunity
  • Cell therapy: mRNA is transfected into the cells ex vivo to alter cell phenotype or function, and these modified cells are subsequently delivered to the patient. e.g. in vitro transcribed chimeric antigen receptor mRNA (IVT CAR mRNA) T cells platform.

There are many benefits of mRNA therapies as compared to similar emerging platforms, such as modular nature with easy to-switch sequences for specifically targeting different proteins or genes, the potential to directly affect the underlying cause of a disease faster manufacturing times compared to antibodies or protein-based drugs, predictable pharmacokinetics, and lack of genome integration.

Categories
  • The proposals will be invited under 2 categories
    • Discovery & Application-oriented Integrated Network Research (expected outcome TRL3-5)
    • Bridging the Gap for scale up (expected outcome TRL5-8)
    • Bridging the Gap for scale up (expected outcome TRL5-8)
Eligibility Criteria
  • Companies established under the Companies Act 2013 and Startups.
  • The Limited Liability Partnership (LLP) incorporated under the Limited Liability Partnership Act,2008.
  • Academic from various Institutions/ Universities /Societies/ Trusts /NGOs /Foundations/ Voluntary Organizations, recognized as a Scientific and Industrial Research Organization (SIRO).

For more information, visit BIRAC.